You are here

Macrogenics

Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug

Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug

BioPharma Dive

DRI Healthcare Trust

type 1 diabetes

Flag link:

Gilead, MacroGenics Unite Against Hematologic Cancers in $1.7B Biobuck Deal

Gilead, MacroGenics Unite Against Hematologic Cancers in $1.7B Biobuck Deal

BioSpace

Gilead Sciences

hematological cancers

drug development

Flag link:

MacroGenics closes solid tumor clinical trial after 7 people die

MacroGenics closes solid tumor clinical trial after 7 people die

Fierce Biotech

clinical trials

Flag link:

MacroGenics flips over an OS dud for cancer drug Margenza in surprising turnaround from earlier data

MacroGenics flips over an OS dud for cancer drug Margenza in surprising turnaround from earlier data

Endpoints

Flag link:

No fast way to eighth place for Incyte

No fast way to eighth place for Incyte

EP Vantage

monoclonal antibodies

Flag link:

ASCO 2021 movers – PDS wins, but big pharma reigns

ASCO 2021 movers – PDS wins, but big pharma reigns

EP Vantage

PDS Biotechnology

Spectrum Pharma

Black Diamond Therapeutics

Alpine Immune Sciences

Harpoon Therapeutics

Flag link:

Macrogenics takes another shot at a novel immune checkpoint

Macrogenics takes another shot at a novel immune checkpoint

EP Vantage

antibody-drug conjugate

Flag link:

Macrogenics takes another shot at a novel immune checkpoint

Macrogenics takes another shot at a novel immune checkpoint

EP Vantage

prostate cancer

metastatic castration-resistant prostate cancer

Flag link:

MacroGenics wins FDA approval of breast cancer drug

MacroGenics wins FDA approval of breast cancer drug

BioPharma Dive

Flag link:

Esmo 2020 – More encouraging signs for checkpoint bispecifics

Esmo 2020 – More encouraging signs for checkpoint bispecifics

EP Vantage

Flag link:

Here's Why MacroGenics Jumped 156.6% in the First Half of 2020

Here's Why MacroGenics Jumped 156.6% in the First Half of 2020

Motley Fool

HER2+ breast cancer

Flag link:

Macrogenics scoops its ASCO bounce

Macrogenics scoops its ASCO bounce

EP Vantage

Flag link:

4 Stocks Battling Breast Cancer

4 Stocks Battling Breast Cancer

Motley Fool

Seattle Genetics

Flag link:

MacroGenics' Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial

MacroGenics' Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial

BioSpace

metastatic HER2-positive breast cancer

clinical trials

Flag link:

ASCO 2019 – Macrogenics builds a case for margetuximab

ASCO 2019 – Macrogenics builds a case for margetuximab

EP Vantage

HER-2 postive breast cancer

Flag link:

Breast cancer survival data buoys Macrogenics and Puma

Breast cancer survival data buoys Macrogenics and Puma

Biopharma Dive

Puma Biotechnology

Flag link:

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

BioCentury

cervical cancer

non-small cell lung cancer

HER2-positive metastatic breast cancer

Flag link:

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer

Endpoints

metastatic breast cancer

clinical trials

Flag link:

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears

Endpoints

bispecific antibodies

clinical trials

Flag link:

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics

Endpoints

PD-1 inhibitors

Flag link:

Pages